5F-ADB

5F-ADB (also known as 5F-MDMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products and has been sold online as a designer drug.[1] 5F-ADB is a potent agonist of the CB1 receptor,[2] though it is unclear whether it is selective for this target. 5F-ADB was first identified in November 2014 from post-mortem samples taken from an individual who had died after using a product containing this substance. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. 5F-ADB is believed to be extremely potent based on the very low levels detected in tissue samples, and appears to be significantly more toxic than earlier synthetic cannabinoid drugs that had previously been sold.[3]

5F-ADB
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.257.468
Chemical and physical data
FormulaC20H28FN3O3
Molar mass377.460 g·mol−1
3D model (JSmol)

In 2018, 5F-ADB was the most common synthetic cannabinoid to be identified in Drug Enforcement Administration seizures.[4] 5F-ADB was also identified in cannabidiol (CBD) products from a US-based CBD manufacturer in 2018.[5]

In the United States, 5F-ADB is a schedule I controlled substance.[6]

5F-ADB was added to the Japanese banned drug list in December 2014.

gollark: ``` osmarks  ~  Downloads  $  exa --tree```
gollark: UNH4XXED!
gollark: Wait, it's Saffy, not Staffy.
gollark: It's an uppercase TRUE for twice the h4xx.
gollark: <@!481036718649114645>.delete = TRUE;

See also

References
  1. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT (Apr 2015). "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry. 407 (21): 6301–15. doi:10.1007/s00216-015-8612-7. PMID 25893797.
  2. Samuel D Banister; et al. (July 2016). "The pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues". ACS Chemical Neuroscience. 7 (9): 1241–54. doi:10.1021/acschemneuro.6b00137. PMID 27421060.
  3. Hasegawa, Koutaro; Wurita, Amin; Minakata, Kayoko; Gonmori, Kunio; Yamagishi, Itaru; Nozawa, Hideki; Watanabe, Kanako; Suzuki, Osamu (2014). "Identification and quantitation of 5-fluoro-ADB, one of the most dangerous synthetic cannabinoids, in the stomach contents and solid tissues of a human cadaver and in some herbal products". Forensic Toxicology. 33: 112–121. doi:10.1007/s11419-014-0259-0.
  4. "Emerging Threat Report: Annual 2018" (PDF). Special Testing and Research Laboratory, Drug Enforcement Administration.
  5. Poklis, Justin L.; Mulder, Haley A.; Peace, Michelle R. (1 November 2018). "The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids". Forensic Science International. 294: e25–e27. doi:10.1016/j.forsciint.2018.10.019. PMC 6321772. PMID 30442388.
  6. "Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I". Drug Enforcement Administration.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.